Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
SS-31
Also known as: Elamipretide, Bendavia, MTP-131, D-Arg-Dmt-Lys-Phe-NH2
SS-31 (elamipretide) is a synthetic tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Developed by Stealth BioTherapeutics, it has been investigated in multiple Phase II and Phase III clinical trials for mitochondrial myopathies (Barth syndrome), heart failure, and age-related macular degeneration. While clinical trial results have been mixed, it has the most advanced clinical development pipeline of any mitochondria-targeted peptide.
Risk Level
Medium RiskDifficulty
Advanced| CAS Number | 736992-21-5 |
| Molecular Formula | C32H49N9O5 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cytochrome c and optimizing electron transport chain efficiency. Reduces electron leak and reactive oxygen species production. Prevents cardiolipin peroxidation and mitochondrial permeability transition pore opening, preserving mitochondrial structure and function under stress.
Dosing Research
Clinical trials used 4-40 mg subcutaneously daily or 0.25 mg/kg/hr IV infusion. Barth syndrome trial used 40 mg SC daily. Underground protocols typically use 5-20 mg SC daily. Treatment durations in trials ranged from single dose to 24 weeks.
Side Effects & Risks
Generally well-tolerated in clinical trials. Injection site reactions are the most common adverse effect. Some trials noted transient elevations in GFR. No major safety signals in Phase II/III data. The compound has received FDA Fast Track and Orphan Drug designations.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.